ArticleHarm reduction journal2020
A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.
Article in Harm reduction journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Ten pressure points in primary care during COVID-19: findings from an international narrative review.BMC primary care · 2025Pooled it
- Hybrid Care Modifications in the Delivery of Nonpandemic Care During the COVID-19 Pandemic: Scoping Review.Journal of medical Internet research · 2026Article
- Factors influencing family physicians' willingness to prescribe opioid agonist therapy using virtual modalities: a qualitative analysis.Frontiers in medicine · 2026Article
- Understanding the use of telemedicine across different opioid use disorder treatment models: A scoping review.Journal of telemedicine and telecare · 2025Article
- Methadone and the Kidney: Dissecting Gender Differences in Inflammation and Oxidative Stress Responses.Addiction & health · 2025Article
- Virtual Primary Care for People With Opioid Use Disorder: Scoping Review of Current Strategies, Benefits, and Challenges.Journal of medical Internet research · 2024Article
- Cross-jurisdictional pandemic management: providers speaking on the experience of Nunavut Inuit accessing services in Manitoba during the COVID-19 pandemic.International journal of circumpolar health · 2023Article
- Developing a Theoretically Informed Implementation Model for Telemedicine-Delivered Medication for Opioid Use Disorder: Qualitative Study With Key Informants.JMIR mental health · 2023Article
- The role of primary care during the pandemic: shared experiences from providers in five European countries.BMC health services research · 2023Article
- Residence in urban or rural counties in relation to opioid overdose mortality among Kentucky hospitalizations before and during the COVID-19 pandemic.The International journal on drug policy · 2023Article
- Should I Stay or Should I Go? A Qualitative Exploration of Stigma and Other Factors Influencing Opioid Agonist Treatment Journeys.International journal of environmental research and public health · 2023Article
- Substance use disorders and COVID-19: reflections on international research and practice changes during the "poly-crisis".Frontiers in public health · 2023Article
- Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.JAMA psychiatry · 2023Review
- COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services.The International journal on drug policy · 2022Article
- Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: A national Delphi study.The International journal on drug policy · 2022Article
- Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.BMC psychiatry · 2022Article
- The impact of the COVID-19 lockdown on services for substance use in Denmark: Implications for meeting users' needs and recommendations for the future.Nordisk alkohol- & narkotikatidskrift : NAT · 2022Article
- Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.The International journal on drug policy · 2022Article
- COVID-19 and substance use disorders: a review of international guidelines for frontline healthcare workers of addiction services.BMC psychiatry · 2022Review
- COVID-19's impact on primary care and related mitigation strategies: A scoping review.The European journal of general practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealth services globally are struggling to manage the impact of COVID-19. The existing global disease burden related to opioid use is significant. Particularly challenging groups include older drug users who are more vulnerable to the effects of COVID-19. Increasing access to safe and effective opioid agonist treatment (OAT) and other harm reduction services during this pandemic is critical to reduce risk. In response to COVID-19, healthcare is increasingly being delivered by telephone and video consultation, and this report describes the development of a national model of remote care to eliminate waiting lists and increase access to OAT in Ireland. PURPOSE AND
findingsThe purpose of this initiative is to provide easy access to OAT by developing a model of remote assessment and ongoing care and eliminate existing national waiting lists. The Irish College of General Practitioners in conjunction with the National Health Service Executive office for Social Inclusion agreed a set of protocols to enable a system of remote consultation but still delivering OAT locally to people who use drugs. This model was targeted at OAT services with existing waiting lists due to a shortage of specialist medical staff. The model involves an initial telephone assessment with COVID-risk triage, a single-patient visit to local services to provide a point of care drug screen and complete necessary documentation and remote video assessment and ongoing management by a GP addiction specialist. A secure national electronic health link system allows for the safe and timely delivery of scripts to a designated local community pharmacy.
conclusionThe development of a remote model of healthcare delivery allows for the reduction in transmission risks associated with COVID-19, increases access to OAT, reduces waiting times and minimises barriers to services. An evaluation of this model is ongoing and will be reported once completed. Fast adaptation of OAT delivery is critical to ensure access to and continuity of service delivery and minimise risk to our staff, patients and community. Innovative models of remote healthcare delivery adapted during the COVID-19 crisis may inform and have important benefits to our health system into the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.